Pipeline

OVERVIEW

A Generational Platform of IgE-Targeted Biologics


RiverCreek Therapeutics is building a multi-generation pipeline of fusion-protein biologics designed to precisely modulate IgE-mediated immune signaling across a broad range of allergic and immune-mediated diseases.


Our pipeline reflects a stepwise evolution in biologic design, progressing from first-generation proof-of-concept molecules to next-generation inhaled therapeutics and future preventive allergy vaccines.

PIPELINE TIMELINE

Lead Program: Egafusp


Pipeline Overview


RiverCreek Therapeutics is developing a fusion-protein therapeutic platform based on a unique mechanism of action that selectively modulates IgE-mediated allergic signaling. By targeting a central upstream pathway in allergic inflammation, this approach is designed to support broad applicability across allergic diseases.


The Company’s lead program, Egafusp, is being developed as a nasal-spray biologic for the treatment of allergic rhinitis. The same underlying molecular platform provides a foundation for future pipeline expansion across additional allergic indications.



Pipeline Evolution

First-Generation RC Fusion Protein

This first-generation program established the biological validity and translational potential of RiverCreek’s approach to IgE modulation.
  • Initial proof-of-concept IgE-targeted fusion protein
  • Preclinical development completed
  • Received IND approval in China

Second-Generation RC-1R Fusion Protein (Egafusp)

RC-1R represents the current clinical development focus of the company.
  • Optimized fusion-protein design
  • Enhanced effectiveness and safety profile
  • Improved stability and manufacturability
  • Designed for intranasal and inhaled delivery

Third-Generation RC Fusion Proteins: Preventive Allergy Vaccines

These programs represent a long-term strategy to move beyond treatment toward disease prevention.

RiverCreek is also developing third-generation RC fusion proteins designed as allergy vaccines.

One example, the KATCIN RC protein, has demonstrated efficacy in preventing cat allergy in animal models. This platform is being expanded to address a wide range of allergens, including:

  • Food allergens
  • Animal allergens
  • Pollen allergens
PIPELINE EXPANSION

Pipeline Expansion: Broad IgE-Driven Indications


Beyond allergic rhinitis, RiverCreek is exploring the potential application of its RC fusion-protein platform across multiple IgE-driven allergic and inflammatory conditions, including:

  • Asthma
  • Allergic conjunctivitis
  • Allergic urticaria
  • Allergic dermatitis
  • Other IgE-mediated systemic allergic diseases


LONG TERM

A Platform for Long-Term Growth


RiverCreek’s pipeline is built not around a single molecule, but around a scalable biologic platform capable of generating:


  • Therapeutic inhaled biologics
  • Localized treatments for mucosal disease
  • Preventive allergy vaccines

This generational strategy supports both near-term clinical milestones and long-term pipeline expansion across the allergic disease spectrum.